Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - horse: vetameg® 50 mg/ml is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: vetameg® 50 mg/ml is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. vetameg® 50 mg/ml is also indicated for the control of inflammation in endotoxemia. horse: there are no known contra-indications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of partu

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - oxytetracycline (unii: x20i9en955) (oxytetracycline anhydrous - unii:slf0d9077s) - oxytetracycline 200 mg in 1 ml - terra-vet® 200 is intended for use in the treatment of the following diseases in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine when due to oxytetracycline-susceptible organisms: cattle: terra-vet® 200 is indicated in the treatment of pneumonia and shipping fever complex associated with pasteurella spp. and haemophilus spp.; infectious bovine keratoconjunctivitis (pink eye) caused by moraxella bovis; foot rot and diphtheria caused by fusobacterium necrophorum; bacterial enteritis (scours) caused by escherichia coli; wooden tongue caused by actinobacillus lignieresii; leptospirosis caused by leptospira pomona; and wound infections and acute metritis caused by strains of staphylococci and streptococci organisms sensitive to oxytetracycline. swine: terra-vet® 200 is indicated in the treatment of bacterial enteritis (scours, colibacillosis) caused by escherichia coli; pneumonia caused by pasteurella multocida; and leptospirosis caused by leptospira pomona. in

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - penicillin g procaine (unii: 17r794esyn) (penicillin g - unii:q42t66vg0c) - penicillin g procaine 300000 [usp'u] in 1 ml - bactracillin g is indicated for treatment of bacterial pneumonia (shipping fever) caused by pasteurella multocida in cattle and sheep, erysipelas caused by erysipelothrix rhusiopathiae in swine, and strangles caused by streptococcus equi in horses.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - oxytetracycline hydrochloride (unii: 4u7k4n52zm) (oxytetracycline anhydrous - unii:slf0d9077s) - oxytetracycline anhydrous 100 mg in 1 ml - a great many of the pathogens involved in cattle diseases are known to be susceptible to oxytetracycline hydrochloride therapy. many strains of organisms, however, have shown resistance to oxytetracycline. in the case of certain coliforms, streptococci and staphylococci, it may be advisable to conduct culture and sensitivity testing to determine susceptibility of the infecting organism to oxytetracycline. in this manner, the likelihood of successful treatment with terra-vet™ 100 solution can be determined in advance.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - penicillin g procaine (unii: 17r794esyn) (penicillin g - unii:q42t66vg0c) - penicillin g 300000 [usp'u] in 1 ml - indications:  pen-aqueous® is indicated for the treatment of: 1. cattle and sheep - bacterial pneumonia (shipping fever) caused by pasteurella multocida. 2. swine - erysipelas caused by erysipelothrix rhusiopathiae. 2. horses - strangles caused by streptococcus equi.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

aspen veterinary resources - tetracycline (unii: f8vb5m810t) (tetracycline - unii:f8vb5m810t) - tetracycline 324 g in 2.27 kg - indications : for use in the control and treatment of the following conditions in swine, calves, and poultry. for swine and calves indications: use for the control and treatment of bacterial enteritis (scours) caused by escherichia coli ; bacterial pneumonia associated with actinobacillus pleuropneumoniae, pasteurella spp. and klebsiella spp. sensitive to tetracycline hydrochloride.  for chickens indications: use for the control of chronic respiratory disease (crd) and air sac disease caused by mycoplasma gallisepticum and escherichia coli ; infectious synovitis caused by mycoplasma synoviae sensitive to tetracycline hydrochloride.  for turkeys indications : use for the control of infectious synovitis caused by mycoplasma synoviae ; bluecomb (transmissible enteritis, coronaviral enteritis) complicated by organisms sensitive to tetracycline hydrochloride.